Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

Denys, Gerald A; Callister, Steven M; Dowzicky, Michael J

doi:10.1186/1476-0711-12-24

Annals of Clinical Microbiology and Antimicrobials

Table 3 Antimicrobial susceptibility for Enterobacteriaceae

From: Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)

		Pacific	Mountain	West North Central	East North Central	Middle Atlantic	New England	South Atlantic	East South Central	West South Central	USA
*E. coli* (ESBL negative)		N = 230	N = 209	N = 801	N = 1411	N = 1811	N = 220	N = 1192	N = 384	N = 385	N = 6643
Amikacin	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	4	8	4	4	4	4	4	8	4	4
	%S	99.6	99.0	100	99.5	99.3	99.5	99.0	98.2	99.7	99.4
Amoxi-clav	MIC ₅₀	4	8	4	8	8	4	4	8	8	8
	MIC ₉₀	16	32	16	16	16	32	32	32	16	16
	%S	77.0	71.8	80.8	75.7	76.1	76.4	75.4	70.1	76.4	76.0
Ampicillin	MIC ₅₀	4	≥64	4	32	≥64	8	≥64	≥64	≥64	32
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	52.6	44.0	54.1	47.4	46.3	51.4	45.4	41.4	43.4	47.2
Carbapenems	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.25	0.25	0.25	0.12	0.25	0.25	0.25	0.25	0.25	0.25
	%S	100	99.0	99.6	99.7	99.6	99.1	99.1	97.7	99.7	99.4
Cefepime	MIC ₅₀	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	MIC ₉₀	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	%S	99.1	99.0	99.6	99.1	98.8	99.1	98.5	98.2	99.5	99.0
Ceftriaxone	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.12	1	0.12	0.25	0.25	0.25	0.25	0.5	0.12	0.25
	%S	97.0	90.4	96.9	96.7	93.9	93.2	94.3	91.1	96.4	94.9
Levofloxacin	MIC ₅₀	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
	MIC ₉₀	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16	≥16
	%S	77.8	76.1	79.7	74.7	72.5	78.6	70.6	72.1	74.0	74.0
Minocycline	MIC ₅₀	1	1	1	1	1	1	1	1	1	1
	MIC ₉₀	8	16	8	8	8	8	8	8	8	8
	%S	86.1	80.4	89.6	84.5	83.4	83.6	85.2	85.9	86.0	85.0
Pip-taz	MIC ₅₀	1	1	1	1	1	1	1	1	1	1
	MIC ₉₀	4	4	4	4	4	4	4	4	4	4
	%S	95.2	94.3	97.5	96.7	97.1	96.8	96.1	96.9	97.7	96.7
Tigecycline	MIC ₅₀	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12
	MIC ₉₀	0.25	0.25	0.25	0.5	0.5	0.25	0.25	0.25	1	0.5
	%S	100	100	99.9	100	99.9	100	100	100	100	100
*K. pneumoniae* (ESBL negative)		N = 159	N = 151	N = 575	N = 1061	N = 1250	N = 150	N = 991	N = 320	N = 294	N = 4951
Amikacin	MIC ₅₀	2	1	1	1	2	1	2	1	1	1
	MIC ₉₀	2	2	2	2	8	2	2	2	2	2
	%S	100	98.7	99.5	99.8	97.2	99.3	98.6	99.1	99.0	98.7
Amoxi-clav	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	8	16	8	8	32	8	16	16	8	16
	%S	95.0	88.7	93.6	90.8	82.2	90.0	87.4	89.1	91.2	88.2
Ampicillin	MIC ₅₀	32	≥64	32	≥64	≥64	≥64	≥64	≥64	32	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	2.5	0.7	1.9	1.2	2.6	4.0	1.7	1.3	1.7	1.9
Carbapenems	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.12	0.5	0.25	0.25	0.5	0.12	0.25	0.12	0.5	0.25
	%S	100	97.4	99.5	98.8	92.5	99.3	97.8	99.1	99.7	97.2
Cefepime	MIC ₅₀	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	MIC ₉₀	≤0.5	≤0.5	≤0.5	≤0.5	4	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	%S	99.4	98.0	99.1	99.4	93.0	99.3	98.2	99.1	99.0	97.4
Ceftriaxone	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.12	0.5	0.25	0.25	8	0.25	0.5	0.25	0.25	0.5
	%S	98.7	91.4	96.5	95.4	84.6	94.0	91.7	96.3	97.3	92.2
Levofloxacin	MIC ₅₀	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06	0.06
	MIC ₉₀	0.25	0.5	0.5	0.5	≥16	1	1	1	0.5	1
	%S	99.4	93.4	96.3	95.5	86.2	90.7	92.9	94.7	97.3	92.7
Minocycline	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	16	16	8	16	16	8	16	16	8	16
	%S	84.9	78.8	85.2	79.5	80.4	85.3	82.0	82.2	83.3	81.6
Pip-taz	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	8	8	8	8	64	4	8	8	8	8
	%S	96.9	92.1	97.6	96.0	88.6	95.3	94.6	97.8	96.6	94.1
Tigecycline	MIC ₅₀	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
	MIC ₉₀	1	1	1	1	2	1	2	2	2	2
	%S	96.2	94.7	95.5	96.4	94.9	97.3	95.9	96.6	96.3	95.8
*Klebsiella oxytoca*		N = 57	N = 50	N = 176	N = 301	N = 279	N = 45	N = 145	N = 49	N = 68	N = 1170
Amikacin	MIC ₅₀	2	2	2	2	2	1	2	2	1	2
	MIC ₉₀	4	4	4	4	4	2	4	4	2	4
	%S	100	96.0	100	99.7	98.9	100	97.2	100	100	99.1
Amoxi-clav	MIC ₅₀	2	2	4	2	4	2	2	2	4	2
	MIC ₉₀	8	32	32	16	32	4	32	8	8	16
	%S	93.0	82.0	82.4	88.7	79.6	97.8	84.8	91.8	91.2	85.6
Ampicillin	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	32	≥64	≥64	≥64	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	0.0	2.0	0.6	2.3	0.0	2.2	2.1	0.0	0.0	1.1
Carbapenems	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.12	0.5	0.25	0.25	0.5	0.25	0.25	0.12	0.25	0.25
	%S	100	94.0	100	98.7	99.6	100	97.9	98.0	100	99.0
Cefepime	MIC ₅₀	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	MIC ₉₀	≤0.5	2	2	1	2	≤0.5	1	≤0.5	≤0.5	1
	%S	100	96.0	98.9	98.7	98.6	100	96.6	100	100	98.5
Ceftriaxone	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.25	4	4	2	16	0.25	4	0.5	0.5	4
	%S	93.0	86.0	83.0	88.7	77.8	97.8	85.5	91.8	92.6	85.6
Levofloxacin	MIC ₅₀	0.03	0.03	0.06	0.06	0.06	0.03	0.03	0.03	0.06	0.06
	MIC ₉₀	0.5	0.12	2	0.25	2	0.06	0.5	0.5	0.5	0.5
	%S	94.7	96.0	90.9	95.0	93.2	100	93.1	95.9	95.6	94.0
Minocycline	MIC ₅₀	1	1	1	2	2	1	1	1	1	1
	MIC ₉₀	2	16	4	8	8	2	4	4	8	8
	%S	98.2	86.0	90.3	89.0	87.1	95.6	91.0	95.9	85.3	89.7
Pip-taz	MIC ₅₀	2	1	1	1	1	1	1	1	2	1
	MIC ₉₀	4	32	≥256	8	≥256	2	8	2	8	16
	%S	94.7	88.0	86.9	92.4	86.0	97.8	91.7	98.0	94.1	90.4
Tigecycline	MIC ₅₀	0.25	0.25	0.25	0.25	0.5	0.25	0.25	0.25	0.5	0.25
	MIC ₉₀	0.5	1	1	1	2	0.5	1	0.5	2	1
	%S	100	98.0	99.4	99.0	98.2	100	97.9	100	100	98.9
*Serratia marcescens*		N = 87	N = 61	N = 302	N = 544	N = 609	N = 67	N = 475	N = 140	N = 136	N = 2421
Amikacin	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	8	8	4	4	4	4	4	4	4	4
	%S	98.9	98.4	99.3	99.3	99.2	100	98.9	97.9	99.3	99.1
Amoxi-clav	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	2.3	6.6	4.6	1.3	3.3	3.0	3.6	2.1	1.5	2.9
Ampicillin	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	2.3	3.3	3.3	1.3	1.3	3.0	1.1	0.7	0.7	1.6
Carbapenems	MIC ₅₀	0.12	0.12	0.12	≤0.06	0.12	0.12	0.12	0.12	≤0.06	0.12
	MIC ₉₀	1	1	1	0.5	1	0.12	0.5	0.25	0.5	1
	%S	97.7	95.1	95.7	96.7	96.4	100	96.2	96.4	100	96.7
Cefepime	MIC ₅₀	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	MIC ₉₀	≤0.5	1	1	4	4	≤0.5	1	≤0.5	1	2
	%S	100	100	98.0	95.4	97.2	100	97.7	97.9	100	97.4
Ceftriaxone	MIC ₅₀	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25
	MIC ₉₀	2	2	4	32	16	1	4	4	2	8
	%S	88.5	86.9	88.7	78.3	77.8	92.5	83.6	86.4	89.7	82.6
Levofloxacin	MIC ₅₀	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12	0.12
	MIC ₉₀	1	0.5	1	2	2	0.5	1	1	0.5	1
	%S	96.6	100	95.0	93.9	93.3	98.5	92.6	96.4	98.5	94.4
Minocycline	MIC ₅₀	2	4	4	4	4	2	4	4	4	4
	MIC ₉₀	8	8	8	8	8	8	8	8	8	8
	%S	86.2	77.0	75.8	74.1	81.0	88.1	78.9	89.3	73.5	78.7
Pip-taz	MIC ₅₀	2	1	1	2	1	1	1	1	2	1
	MIC ₉₀	8	8	4	8	8	4	4	4	4	8
	%S	98.9	96.7	97.0	93.6	94.1	98.5	96.2	97.1	97.8	95.5
Tigecycline	MIC ₅₀	1	1	1	1	1	1	1	1	1	1
	MIC ₉₀	2	2	2	2	2	2	2	1	2	2
	%S	98.9	91.8	97.4	96.5	95.4	97.0	95.4	97.9	91.9	95.9
*Enterobacter* spp.		N = 227	N = 192	N = 770	N = 1351	N = 1500	N = 198	N = 1118	N = 339	N = 370	N = 6065
Amikacin	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	4	4	2	4	4	2	4	2	4	4
	%S	100	99.5	99.5	98.7	98.1	99.5	99.2	98.8	98.6	98.9
Amoxi-clav	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	4.8	4.7	7.3	3.3	3.7	2.5	5.5	6.2	5.1	4.7
Ampicillin	MIC ₅₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	MIC ₉₀	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64	≥64
	%S	2.2	6.3	5.8	2.7	2.9	3.5	2.8	2.9	3.0	3.3
Carbapenems	MIC ₅₀	≤0.06	≤0.06	≤0.06	≤0.06	0.12	≤0.06	≤0.06	≤0.06	≤0.06	≤0.06
	MIC ₉₀	0.5	1	0.5	0.5	1	0.5	0.5	0.5	0.5	0.5
	%S	100	97.4	98.6	97.9	96.1	99.5	97.9	97.3	97.8	97.6
Cefepime	MIC ₅₀	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5	≤0.5
	MIC ₉₀	2	4	2	4	4	2	4	4	2	4
	%S	95.6	96.9	97.0	97.1	95.6	97.5	94.7	94.4	97.6	96.1
Ceftriaxone	MIC ₅₀	0.25	0.5	0.25	0.25	0.25	0.25	0.25	0.25	0.25	0.25
	MIC ₉₀	16	64	32	32	64	32	64	64	32	64
	%S	79.7	63.5	76.9	72.8	63.8	74.7	71.7	64.3	76.8	70.7
Levofloxacin	MIC ₅₀	0.03	0.06	0.06	0.06	0.06	0.03	0.06	0.06	0.06	0.06
	MIC ₉₀	0.25	0.5	0.5	1	4	0.5	4	≥16	0.5	2
	%S	97.8	93.2	93.9	93.0	89.4	98.0	86.8	85.0	93.5	91.0
Minocycline	MIC ₅₀	2	2	2	4	2	2	2	2	2	2
	MIC ₉₀	8	16	16	16	16	4	8	8	16	16
	%S	87.2	78.1	79.7	77.1	76.3	90.4	80.8	81.1	77.6	79.0
Pip/taz	MIC ₅₀	2	2	2	2	2	2	2	2	2	2
	MIC ₉₀	64	128	64	64	64	64	64	64	64	64
	%S	85.0	80.2	86.5	84.3	80.9	85.4	82.0	80.2	83.2	83.0
Tigecycline	MIC ₅₀	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
	MIC ₉₀	1	2	1	1	2	1	2	2	2	2
	%S	96.0	93.2	96.4	96.3	93.7	98.0	94.8	94.7	97.3	95.3

% S, % susceptible, amoxi-clav amoxicillin-clavulanate, pip-taz piperacillin-tazobactam, carbapenems = imipenem/meropenem.

Back to article page

ISSN: 1476-0711

Contact us

Submission enquiries: journalsubmissions@springernature.com